Zealand and Roche report Phase 2 data for amylin therapy amid Lilly competition
Zealand Pharma and Roche have released initial Phase 2 results for petrelintide, an amylin-based treatment for obesity and diabetes. The companies are trying to challenge Eli Lilly in that market, though the competitive hurdle remains.
Zealand Pharma and Roche have released initial Phase 2 results for petrelintide, an amylin-based candidate intended to treat obesity and diabetes. The therapy is entering a market where Eli Lilly is already a competitor. The companies are trying to establish a position in that space, but the summary indicates that the competitive hurdle remains.
If petrelintide advances, people with obesity or diabetes could gain another treatment option, and competition among drugmakers may intensify. That could influence pricing, access, and patient choice over time, though Phase 2 results alone may not confirm real-world benefit. Clinicians, patients, and health systems may watch the program closely as it develops.